{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:50:52Z","timestamp":1777978252355,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>When an initial antiretroviral therapy (ART) regimen is effective and well-tolerated, it can be maintained for years as long as the patient adheres. Prior research has revealed that shorter initial ART duration is associated with regimen type, female sex, injection drug use as the HIV transmission category, and lower baseline CD4 count. We examined potential factors associated with initial regimen discontinuation among a subset of newly diagnosed virally unsuppressed PWH in the DC Cohort, an ongoing prospective observation study that uses electronic health record data from clinic sites to collect relevant information, including demographic and clinical information. Participants were excluded from the analysis if they had less than 6 months of follow-up and were virally suppressed at enrollment. There were 479 individuals included in the study. The median age of participants was 33.9 years [interquartile range (IQR) 26\u201343.9]. The sample was predominantly male (79.1%) and of Black race (70.8%). Over half of the study participants (56.4%) attended community-based clinic sites. The median time to the discontinuation of initial ART was 2.7 years [95% confidence interval (CI): 2.3, 3.4]. Females had a shorter time to ART discontinuation [adjusted hazard ratio (aHR) 1.55, 95% CI: 1.14, 2.11] as did individuals who started on a protease inhibitor-based regimen versus integrase strand transfer inhibitors (aHR 1.87, 95% CI: 1.34, 2.61) and those receiving HIV care at a community-based site (aHR 1.46, 95% CI: 1.11,1.93). Although limited by lack of reason for discontinuation, we demonstrated that ART-na\u00efve women, community clinic attendees, and patients starting on PIs had a shorter duration of initial ART. More anticipatory guidance may be needed to help patients stay on their initial therapy and manage the side effects or to be flexible in trying different regimens.<\/jats:p>","DOI":"10.1089\/aid.2024.0002","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T12:36:09Z","timestamp":1720010169000},"page":"671-679","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors Associated with Time to Initial Antiretroviral Therapy Discontinuation in the DC Cohort"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-2311","authenticated-orcid":false,"given":"Morgan E.","family":"Byrne","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna B.","family":"Resnik","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Horberg","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Mid-Atlantic Permanente Research Institute, Oakland, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-0217","authenticated-orcid":false,"given":"Alan E.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda D.","family":"Castel","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-3845","authenticated-orcid":false,"given":"Anne K.","family":"Monroe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000233310.90484.16"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_3_6_4_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2014. Available from: http:\/\/aidsinfo.nih.gov\/ContentFiles\/Adultand. [Accessed April 15 2024]."},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30053-X"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002075"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002603"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002447"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01428-1"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05816-5"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3297"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30016-9"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00027-2"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00328-6"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01469-6"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1084"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz237"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010161"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001708"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06919-6"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002210"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0107-7"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258533"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003310-00005"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25149"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528120-00003"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173338"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3194"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.07.005"},{"key":"e_1_3_6_31_2","unstructured":"District of Columbia Department of Health. HIV\/AIDS Hepatitis STD & TB Administration. Annual Epidemiology & Surveillance Report. Data through December 2022. 2023. Available from: https:\/\/dchealth.dc.gov\/service\/hiv-reports-and-publications [Last accessed: April15 2024]."},{"key":"e_1_3_6_32_2","unstructured":"District of Columbia Department of Health. DC Ends HIV Plan. 2020. DCEndsHIV.org [Last accessed: April15 2024]."},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv176"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002236"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.19000023"},{"key":"e_1_3_6_36_2","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal [Last accessed: May15 2024]."},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2014.0199"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2010.484456"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2103-8"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2024.0002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2024.0002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2024.0002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:17:01Z","timestamp":1777367821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/aid.2024.0002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1089\/aid.2024.0002"],"URL":"https:\/\/doi.org\/10.1089\/aid.2024.0002","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}